Sinopharm revenue falls 1.13 percent: Sinopharm stock trades at 5.81 times earnings

Published on 10/20/2026 at 21:20 | Editorial responsibility: Rafael Müller, Editor-in-Chief AD HOC NEWS

Retail pharmacy revenue rose 8.58 percent in first-half 2026. Sinopharm stock was at EUR 1.73 at Lang & Schwarz on October 20, 2026.

Revenue and valuation in focus

Sinopharm reported first-half 2026 revenue of RMB 282.80 billion, down 1.13 percent, on September 23, 2026.
Pharmaceutical retail revenue increased 8.58 percent in the six months ended June 30, 2026.
Sinopharm stock was at EUR 1.73 at Lang & Schwarz on October 20, 2026 at 9:15 p.m. CEST.
The stock had a price-to-earnings ratio of 5.81 and a market capitalization of HKD 47.96 billion as of October 20, 2026.

Sinopharm, CNE100000FN7, Illustration mit AI erstellt.

Sinopharm Group reported first-half 2026 revenue of RMB 282.80 billion, down 1.13 percent from the prior-year period, while net profit fell 2.95 percent to RMB 5.18 billion, according to Futu on September 23, 2026. Sinopharm stock was at EUR 1.73 at Lang & Schwarz on October 20, 2026 at 9:15 p.m. CEST.

Retail offsets distribution pressure

The half-year figures show a split operating picture. Pharmaceutical distribution revenue declined 1.39 percent year over year, while medical device distribution revenue fell 0.35 percent. Pharmaceutical retail revenue rose 8.58 percent in the six months ended June 30, 2026, partly offsetting the weaker wholesale businesses, according to Futu.

What does the valuation show?

Sinopharm's Hong Kong-listed shares were last quoted at HKD 15.37 on October 20, 2026 at 4:08 p.m. HKT. The stock carried a price-to-earnings ratio of 5.81 and a market capitalization of HKD 47.96 billion on that date. The figures place valuation alongside the revenue decline, rather than treating the retail increase as a group-wide recovery.

Peers provide a wider frame

Comparison with peers

Sino Biopharmaceutical (HKEX, HKD): up 2.86 percent, price-to-earnings ratio 34.75, market capitalization HKD 96.13 billion.

WuXi Biologics (HKEX, HKD): up 3.84 percent, price-to-earnings ratio 35.78, market capitalization HKD 206.02 billion.

Stock and business dates

The interim reporting period ended June 30, 2026, and the report was published on September 23, 2026. The interim report also said the board recommended no interim dividend for the period, while the company disclosed an August equity transfer agreement involving a 51 percent stake in Guorui Pharmaceutical, according to Futu.

Sinopharm remains tied to retail growth

The key contrast is clear: group revenue declined 1.13 percent, but pharmaceutical retail revenue increased 8.58 percent during the same first-half period. That split gives investors a measurable way to track whether the retail business can offset distribution pressure in later reports. The further course of trading is shown by the continuously updated real-time quote of Sinopharm stock.